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Abstract
Schistosomiasis is a tropical parasitic disease afflicting ~200million people worldwide and
current therapy depends on a single drug (praziquantel) which exhibits several non-optimal
features. These shortcomings underpin the need for next generation anthelmintics, but the
process of validating physiologically relevant targets (‘target selection’) and pharmacologically
profiling them is challenging. Remarkably, even though over a quarter of current human thera-
peutics target rhodopsin-like G protein coupled receptors (GPCRs), no library screen of a flat-
worm GPCR has yet been reported. Here, we have pharmacologically profiled a schistosome
serotonergic GPCR (Sm.5HTR) implicated as a downstreammodulator of PZQ efficacy, in a
miniaturized screening assay compatible with high content screening. This approach employs
a split luciferase based biosensor sensitive to cellular cAMP levels that resolves the proximal
kinetics of GPCRmodulation in intact cells. Data evidence a divergent pharmacological signa-
ture between the parasitic serotonergic receptor and the closest humanGPCR homolog
(Hs.5HTR7), supporting the feasibility of optimizing parasitic selective pharmacophores. New
ligands, and chemical series, with potency and selectivity for Sm.5HTR over Hs.5HTR7 are
identified in vitro and validated for in vivo efficacy against schistosomules and adult worms.
Sm.5HTR also displayed a property resembling irreversible inactivation, a phenomenon dis-
covered at Hs.5HTR7, which enhances the appeal of this abundantly expressed parasite
GPCR as a target for anthelmintic ligand design. Overall, these data underscore the feasibility
of profiling flatwormGPCRs in a high throughput screening format competent to resolve differ-
ent classes of GPCRmodulators. Further, these data underscore the promise of Sm.5HTR as
a chemotherapeutically vulnerable node for development of next generation anthelmintics.
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Author Summary
Parasitic flatworms express a diverse array of G protein coupled receptors, but our knowl-
edge of their pharmacological profile is limited. No high throughput screen of a flatworm
GPCR has been reported, even though these targets have precedent for high druggability
and functionality in the chemotherapeutically vulnerable excitable cell niche. The goal of
this study was to establish a method for profiling flatworm G protein coupled receptors
that can be scaled to high content screening. Using a cAMP biosensor, we have performed
a proof of principle miniaturized screen on a schistosome serotonergic GPCR that resolves
new ligands that potently and selectivity block 5-HT receptor activity in vitro, and 5-HT
evoked responses in schistosomules and adult worms. This approach evidences the phar-
macological divergence of a parasitic GPCR from the closest human homolog and a capac-
ity for high content interrogation of flatworm GPCR properties and ligand specificities.
Introduction
The neglected tropical disease Schistosomiasis is the most socioeconomically devastating hel-
minth infection, and the second most burdensome parasitic infection behind malaria, infecting
over 200 million people worldwide [1]. Infected individuals are treated by the drug praziquan-
tel (PZQ), the mainstay therapeutic for disease control.
PZQ was originally developed during the 1970s, and the continued effectiveness of this
agent over four decades of usage for treating a variety of parasitic infections has proven criti-
cally impactful [1]. Indeed this clinical efficacy has ironically proven to be a factor that has
restrained efforts to develop alternative therapies, and at the most basic level, define how PZQ
works. However several features of PZQ remain less than ideal and require improvement. First,
our lack of mechanistic understanding of how PZQ works has proved a roadblock in the ratio-
nal design of new drugs. There is a need to identify new druggable targets that exploit broader
vulnerabilities within PZQ-sensitive pathways [2–4]. Second, our inability to improve on PZQ
by chemical derivatization of the drug: all PZQ derivatives synthesized to date are less effective
than the parent compound. The need is to identify novel structural pharmacophores that
impair parasite viability. Third, the inability of PZQ to kill all parasitic life cycle stages. Juvenile
worms are refractory to PZQ [5,6], possibly a contributory factor driving development of drug
resistance [5,7]. The need is to identify new targets expressed throughout all lifecycle stages
that are ideally conserved in other PZQ-sensitive parasites. Fourth, sub-optimal cure rates in
the field: PZQ requires multiple drug dosings to achieve maximal cure rates for schistosomiasis,
a regimen which is not always executed in mass drug administration efforts [8,9]. Therefore,
there is clear opportunity to improve on the clinical penetrance of PZQ. These issues support
efforts to identify new, druggable targets for development of next generation anthelmintics.
A logical place to start is with downstream effectors within the broader PZQ interactome.
Over the last few years, therefore, our laboratory has attempted to bring fresh perspective to
understand how PZQ works based upon a serendipitous basic science finding. During regener-
ation of the planarian flatworm D. japonica–a widely used regenerative biology model [10]–
PZQ miscued polarity signaling to cause regeneration of bipolar (‘two-headed’) worms with
dual, integrated organ systems [11]. This visually striking phenotype, coupled with the tracta-
bility of the planarian system to in vivo RNAi, allowed us to progressively define pathways
engaged by PZQ in vivo [11–14]. These studies culminated in a model where PZQ acts as an
ergomimetic [13] with in vivo PZQ efficacy regulated by the opposing functionality of dopami-
nergic and serotonergic neurons [11–14], known regulators of muscular activity, the tissue
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where planarian polarity determinants reside [15]. The serotonergic and dopaminergic G pro-
tein coupled receptors (GPCRs) engaged by activity of these bioaminergic neurons therefore
represent potential downstream PZQ effectors. Their engagement by ligands, as shown for bro-
mocriptine and other ergot alkaloids, phenocopy PZQ action in vivo [13,14].
This is an important realization as flatworm G protein coupled receptors (GPCRs) are logi-
cal candidates for antischistosomal drug development efforts. Over one quarter of current ther-
apeutics target rhodopsin-like GPCRs [16]. However, barriers have been a lack of
understanding of the physiology of specific GPCRs from within the broad GPCR portfolio
(~75–120 in S.mansoni [17–19]) expressed by these organisms, as well as struggles optimizing
functional expression of individual flatworm GPCRs in heterologous assay systems. However
several groups have now begun to define a role for specific GPCRs within the chemotherapeuti-
cally vulnerable excitable cell niche [13,20–22], highlighting the key challenge of optimizing
robust platforms for pharmacologically profiling these GPCRs in a miniaturized format com-
patible with high throughput screening (HTS). To our knowledge, no library screen of a flat-
worm GPCR has yet been reported. Prior studies have simply relied on interrogation of
expressed GPCRs against handfuls of ligands selected around inferred agonist specificity.
Therefore the goal of this study was to establish a method for profiling flatworm GPCRs
that can be effectively scaled to HTS. Our priorities for a platform were: first, a robustness for
miniaturization into a multiwall plate format to permit chemical library screening, and second,
use of a proximal readout of receptor activity within intact cells to enable real time monitoring
of GPCR activity that can resolve different types of modulators (full, partial and inverse ago-
nists, allosteric modulators). One technology that fulfills these requirements employs a biolu-
minescent cAMP reporter to monitor the activity of Gs and Gi-coupled GPCRs, marketed as
GloSensor. The assay is based upon a crucially permutated form of firefly luciferase incorporat-
ing a cAMP-binding domain from PKA, such that cAMP-binding causes a conformational
change in the enzyme that enhances the luminescent signal [23]. The dynamic range and sensi-
tivity of the biosensor has been shown to be compatible with a variety of HTS assays [23,24].
To evaluate this technology, we applied this approach to pharmacologically profile a S.man-
soni serotonergic GPCR (Sm.5HTR) that has been shown in vitro to respond to 5-HT through
elevation of cAMP [20]. Sm.5HTR is the parasitic homologue of the planarian serotonergic
GPCR (S7.1) that we have recently shown modulates the efficacy of PZQ in vivo [13]. However,
as with most flatworm GPCRs, little is known about the pharmacology of this receptor. An ini-
tial characterization revealed blockade of 5-HT evoked signals in the presence of high concen-
trations (100μM) of mammalian bioaminergic blockers [20]. Here, we have applied the
GloSensor assay in a proof of principle pilot screen for flatworm GPCR modulation. Our data
evidence the extent of pharmacological divergence between the schistosome receptor and the
human 5-HT7-receptor homolog (Hs.5HT7R), and reveal new ligands and compound series
selective for the parasitic GPCR. Finally, despite these differences in ligand selectivity, we dem-
onstrate conservation of an unusual antagonist-evoked inactivation mechanism for Sm.5HTR,
a pharmacological phenomenon also exhibited at Hs.5HT7R [25,26], where exposure to a sub-
set of antagonists results in a prolonged inactivation of signaling activity from the receptor.
This property enhances the attractiveness of Sm.5HTR as an anthelmintic drug target.
Results
Functional expression of a schistosome 5-HT receptor
In schistosome parasites, 5-HT is myoexcitatory: exogenous addition of 5-HT to schistoso-
mules causes an increase in basal contractility and 5-HT also increases mobility of adult worms
[27,28]. While this action has long been known, it is only in the last several years that the
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relevant receptors mediating the effects of 5-HT in flatworms have been identified [13,20]. The
most abundant schistosome 5-HT receptor in adult worms from transcriptomic analysis [29],
is a recently characterized GPCR christened Sm.5HTR [20].
Expression of an epitope tagged Sm.5HTR construct in HEK293 cells resulted in expression
of a ~56 kDa product, consistent with the predicted size (Fig 1A). To assess functionality of
this receptor, we utilized the GloSensor cAMP assay as a real-time luminescent readout of cel-
lular cAMP levels. This ‘biosensor’monitors luminescence from a firefly luciferase that is engi-
neered to be cAMP sensitive by incorporation of a cAMP binding domain into the
recombinant luciferase. The presence of substrate and cAMP results in an enhanced lumines-
cence from the transfected GloSensor construct (Fig 1B), allowing real time monitoring of
cAMP levels within intact cells. This can be seen in HEK293 cells transfected with both
Sm.5HTR and GloSensor, where application of 5-HT evoked an increase in luminescence val-
ues over time (Fig 1C). No changes in cAMP were elicited in HEK293 cells transfected with the
biosensor alone (Fig 1C).
Optimization of assay conditions
Measurements of assay sensitivity were made from 5-HT evoked luminescence signals in cells
plated in 96-well plates transfected with cAMP biosensors exhibiting either high affinity (‘F20’
construct) or low affinity (‘F22’ construct) for cAMP (Fig 2A). As expected, the magnitude of
the luminescence signal varied with 5-HT application in a dose-dependent manner with both
biosensor constructs in Sm.5HTR transfected cells (Fig 2B). With the higher affinity 20F sen-
sor, the EC50 for cAMP generation was 703±90nM (n = 3, Fig 2B and Table 1), with the dose
Fig 1. Functional expression of Sm.5HTR. (A) Western blot of myc-tagged Sm.5HTR (Genbank KF444051.1) in HEK293 cells. L, ladder. (B)
Schematic of GloSensor assay depicting generation of cAMP by activation of Sm.5HTR (blue) which couples to endogenous G proteins and adenylate
cyclase to increase cAMP levels. cAMP binding to the permuted luciferase construct leads to enhanced luminescence in the presence of substrate. (C)
Functional expression of Sm.5HTR using this assay. In cells transfected with the biosensor (22F variant) addition of 5-HT (10μM) caused an increase
in luminescence in Sm.5HTR transfected (blue symbols), but not control cells (open symbols).
doi:10.1371/journal.ppat.1005651.g001
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Fig 2. Optimization of cAMP bioluminescent sensor for monitoring Sm.5HTR activity. (A) Timecourse
of cAMP changes following application of 5-HT (10μM) in HEK293 cells transfected with Sm.5HTR (circles) or
untransfected controls (triangles). Assays are shown in the presence (open symbols) and absence (solid
symbols) of a phosphodiesterase inhibitor (IBMX, 200μM). Luminescence values were recorded every 3
minutes in cells transfected with the high affinity (F20, left) or low affinity (F22, right) cAMP biosensor. Inset
shows data for Sm.5HTR in the absence of IBMX on a rescaled y-axis. (B) 5-HT dose response curves from
experiments such as those described in (A) for F20 (left) and F22 (right) in the presence (open) or absence
(solid) of IBMX. Control data using untransfected cells are also shown (triangles). Note log scale for
responses with 22F. (C) Z’ values calculated for 5-HT evoked signals over time under the conditions
described previously. (D) Real time comparison of methiothepin pretreatment on 5-HT evoked changes in
cAMP. One cohort of cells was preincubated with methiothepin (10μM, open circles), prior to addition of 5-HT
(10μM) and IBMX (200μM, closed triangle) and then forskolin (20μM, open triangle). (E) 5-HT dose response
curves for Sm.5HTR (solid) and Sm.5HTRL (open). Inset, schematic comparison of schistosome 5HT
receptor isoforms. Sm.5HTRL is a longer isoform with additional sequence at the N-terminus and third
intracellular loop. (F) Kinetics of 5-HT response (10μM) for Sm.5HTR and Sm.5HTRL.
doi:10.1371/journal.ppat.1005651.g002
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response relationship shifting to higher values with the 22F sensor as previously established
[23]. The magnitude of the response was greatest in media supplemented with 3-isobutyl-
1-methylxanthine (IBMX, 200μM) to block cAMP degradation. In the presence of IBMX,
higher overall luminescence values were recorded with peak signal to background changes of
~1.7-fold and ~15.1-fold for 20F and 22F respectively (Fig 2A and 2B), providing a good signal
to background window for monitoring receptor activation.
The robustness of these cAMP assays was assessed by calculating the Z’ factor (Z’), a widely
used indicator of assay quality in high throughput screening applications [30]. Z’ values over
0.5 are considered a prerequisite for executing high throughput screens. Calculations of Z’ were
made at different timepoints during the agonist response, averaging 6 replicate wells within a
96 well plate. In our hands, the highest Z’ scores were obtained with the F22 sensor supple-
mented with IBMX (Fig 2C), and these conditions were used for all subsequent assays. Accept-
able Z’ values were also obtained with cells in suspension (Table 1) and under conditions of
further miniaturization to 384-well plates (Fig A in S1 Text).
Unlike assays requiring cell lysis for fixed timepoint measurement, the live cell biosensor
allowed real time monitoring of cellular cAMP levels throughout ongoing experimental manip-
ulations. Fig 2D demonstrates antagonism of 5-HT stimulated cAMP generation by the anti-
psychotic methiothepin [31], with cellular responsiveness demonstrable by the subsequent
addition of forskolin. Dose response analyses also confirmed preferential activation of
Sm.5HTR by 5-HT compared with other bioaminergic agonists (Fig B in S1 Text). Finally, we
used this assay to compare responsiveness from two different isoforms of Sm.5HTR which
have been isolated–the originally published sequence Sm.5HTR [20] and a longer isoform
(Sm.5HTRL) containing addition sequence at the NH2-terminus and within the third intracel-
lular loop (Fig 2E, inset). Both isoforms were activated by 5-HT, with Sm.5HTRL displaying
~10-fold greater sensitivity (EC50 0.2±0.03μM vs 2.0±0.2μM, Fig 2E) but a similar kinetic
response (Fig 2F).
Pharmacological profiling of Sm.5HTR against a GPCRmodulator
library
Sequence homology identifies Sm.5HTR as a member of the SER7 clade of serotonin receptors,
clustering with planarian S7 receptors [13] and with Hs.5HT7R as the closest human homolog
[20]. To characterize the extent of pharmacological conservation between the parasite and
Table 1. Summary statistics for live cell GloSensor cAMP assays on Sm.5HTR. Z’ factor, signal window and EC50 were calculated at 60 minutes after
delivery of 5-HT (10μM).
Adherent Cells F20 F22
(-) IBMX (+) IBMX (-) IBMX (+) IBMX
Z’ factor* 0.4 0.7 -0.1 0.7
Signal window** 3.1 3.6 -0.3 12.3
EC50 0.7 μM 0.9 μM 16.1 μM 2.0 μM
Suspension Cells F20 F22
(-) IBMX (+) IBMX (-) IBMX (+) IBMX
Z’ factor* 0.9 0.2 0.7 0.9
Signal window** 37.5 0.7 7.4 40.8
EC50 1.4 μM 1.0 μM 4.2 μM 3.8 μM
* Z’ factor calculated for vehicle control and 5-HT (10μM); Z’ = 1 - (3(stdevmax + stdevmin) / (meanmax—meanmin).
** Signal window calculated for vehicle control and 5-HT (10μM), defined as SW = (meanmax—meanmin—3(stdevmax + stdevmin)) / stdevmax.
doi:10.1371/journal.ppat.1005651.t001
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human serotonin receptor, we used the miniaturized cAMP assay to screen a commercial
GPCR compound library (~250 compounds) for inhibitors of these receptors. An inhibitor
screen was prioritized simply because of the improved likelihood of detecting antagonists over
agonists (need to exclude false positives from stimulation of endogenous receptors), and the
utility of these agents for blocking parasite motility.
The protocol for screening is shown schematically in Fig 3A. HEK293 cells transiently trans-
fected with either the human 5HT7 receptor (Hs.5HT7R) or the schistosome receptor
(Sm.5HTR) were exposed to test ligands in a 96-well plate format. After addition of test com-
pounds, 5-HT was then added to each well at a concentration corresponding approximately to
the EC80 of each receptor to assess blockade of 5-HT effects by prior compound addition.
Luminescence was then read at a fixed time point (t = 60min, Fig 3A). Hits were assigned as
compounds that evoked a50% decrease in luminescence output at the fixed time sampling
point (Fig 3B). These experiments identified 25 compounds as potential antagonists of
Sm.5HTR evoked cAMP generation (Fig 3B).
Two sets of validation experiments were then performed in order to remove false ‘hits’
from the dataset. First, the same library was also screened against naive HEK293 cells as a con-
trol for responses resulting from engagement of endogenous GPCRs (Fig 3C). This analysis
identified 14 compounds in the library that activated endogenous Gs-coupled GPCRs in
HEK293 cells [32]. Second, to exclude ligands that inhibited either cAMP production (for
example, through activation of endogenous Gi-coupled GPCRs) or directly impaired the activ-
ity of the luciferase biosensor, the library was screened against forskolin-evoked increases in
cAMP (Fig 3D). This analysis identified 7 compounds that decreased luminescence values
>2-fold in forskolin-treated control cells. These 21 compounds were ‘masked’ from the experi-
mental dataset and the overall pharmacological profile of Sm.5HTR and Hs.5HTR7 were then
represented as a heat map to depict ligand-evoked changes in cAMP levels (Fig 3E). This visual
representation conveys in a simple manner the extent of pharmacological divergence between
the human and schistosome GPCRs. Some drugs displayed a unique affinity for Sm.5HTRs,
others preferentially modulated Hs.5HT7R, and some ligands blocked both receptors. Overall,
23 compounds were retained for subsequent validation as antagonists of Sm.5HTR with only
a minor proportion of these compounds (7 ‘hits’) showing inhibition at both the human and
parasite receptor (Fig 3E, inset). A simple overview of the pharmacological specificity of the
compounds identified as antagonists using the ligand classification key associated with the
library was also informative (Fig C in S1 Text). The types of ligand classes–if not compound
identities–that inhibited each serotonergic GPCR was broadly similar. The only notable differ-
ence was blockade of Sm.5HTR by some cholinergic ligands, which was not apparent for
Hs.5HT7R.
To confirm ‘hit’ validity, complete dose response relationships were then examined for all
compounds that inhibited 5-HT evoked signals by50%. Examples of these assays (Fig 4) con-
firm the designation of compounds showing selective inhibition of the parasite serotonin
receptor (Fig 4A, top), blockade of 5-HT receptors from both species (Fig 4A, middle) and
preferential antagonism of the human 5-HT receptor (Fig 4A, bottom). Calculation of a selec-
tivity ratio (IC50 (Hs.5HT7R) / IC50 (Sm.5HTR)) for these antagonists (Fig 4B) revealed a
broad continuum of GPCR selectivity among from the screened compounds. Four ligands
demonstrated clear selectivity for Sm.5HTR (alfuzosin, orphenadrine, atomoxetine and rotun-
dine, Fig 4A and 4B), of which rotundine displayed the most sensitive IC50 value (IC50 = 701
±207nM). These ligands also inhibited 5-HT evoked cAMP generation through Sm.5HTRL
(Fig D in S1 Text). However, none of these compounds directly affected biosensor lumines-
cence or cell viability of untransfected cells of at screened dosages (Fig E in S1 Text).
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Fig 3. Pharmacological profiling of Sm.5HTR. (A) Schematic of assay workflow for screening a library of known GPCR ligands against
HEK293 cells expressing either Sm.5HTR or Hs.5HT7. Cells transfected with either 5HTR and F22 cAMP biosensor were plated in 96-well
format and exposed to test compounds (10μM). 5-HT was added after 30mins (at an EC80 concentration) after which luminescence values
were recorded (time = 60min). (B) Scatter plots summarizing effects of test compounds on the Sm.5HTR response to 5-HT (dotted line
highlights threshold for defining compound ‘hits’). Hits were defined at a threshold of50% inhibition relative to control wells (DMSO only,
open symbols). (C) Compounds were also screened against HEK293 cells expressing the F22 sensor alone (no Sm.5HTR) to screen for
cAMP generation at endogenous receptors. For reference, a forskolin data point is shown in red. (D) Compounds were also screened against
SchistosomeGPCR Ligand Discovery
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Direct interrogation of Sm.5HTR
While the above data provide proof of principle for interrogation of a flatworm GPCR against
a compound library in a miniaturized format, we were also curious to use the assay to investi-
gate the properties of specific ligands prioritized by our prior work. First, we were interested in
profiling specific ergot alkaloids on the basis of observations showing these compounds act as
efficacious modulators of flatworm physiology [27,33,34]. Certain ergot alkaloids inhibit schis-
tosomule contractility, while others stimulate hyperactivity [13]. In regenerating planarians,
the ergopeptide bromocriptine evoked bipolarity at concentrations 100-fold less than PZQ
[14], implying a potency of this class of agents against flatworm bioaminergic receptors. How-
ever, the structure-activity relationships (SAR) of ergots at flatworm GPCRs and relative selec-
tivity over human receptors is unknown. Second, we have previously suggested an ergomimetic
quality to PZQ action, raising the possibility that PZQ itself acts as a direct ligand of flatworm
bioaminergic receptors likely as a serotonergic antagonist [13]. Therefore, screening for PZQ
activity against Sm.5HTR was also investigated. Third, Hs.5HTR7 displays a property of
pseudo-irreversible antagonism, where a subset of ligands effect a persistent inactivation of the
receptor persistent beyond the duration of drug exposure [25,26]. Is this phenomenon con-
served at Sm.5HTR? Finally, guided by the chemical library data, we performed a secondary
screen of compounds structurally related to ‘hits’ from the initial drug screen (‘SAR by com-
merce’). Each of these experiments are discussed in turn below.
First, is Sm.5HTR activity modulated by ergot alkaloids? Several ergot alkaloids were
screened against Sm.5HTR and these experiments revealed agonist activity of ergotamine and
dihydroergotamine, which have previously shown to stimulate the basal contractility of schis-
tosomules [13]. Ergotamine and dihydroergotamine were more potent (EC50 of 232nM and
315nM, respectively) than 5-HT (EC50 of ~1μM, Fig 5A), but with a lower maximal response
suggestive of partial agonism. By contrast, other ergoline ligands, bromocriptine, metergoline
and the hallucinogen lysergic acid diethylamide (LSD), an agonist at vertebrate 5-HT2A recep-
tors, exhibited no efficacy at Sm.5HTR (Fig 5A). To investigate further the nature of these inac-
tive ligands, the ability of increasing doses of bromocriptine (Fig 5B), metergoline (Fig 5C) and
LSD (Fig 5D) to modulate 5-HT evoked cAMP accumulation at the Sm.5HTR was assessed.
Each of these ergot ligands caused a right-shift in the 5-HT dose-response relationship consis-
tent with competitive antagonism (Fig 5B–5D). At higher concentrations (>10μM) bromocrip-
tine and LSD showed almost complete inhibition of 5-HT evoked cAMP generation. To
quantify the extent of antagonism, a Schild regression analysis [35,36] was performed which
yielded affinity constants (KB) of 410 nM for bromocriptine, 629nM for LSD and 4530 nM for
metergoline (Fig 5F). These data show that ergot alkaloid derivatives can act as potent modula-
tors of schistosome 5-HTRs.
Second, screening of PZQ against Sm.5HTR in this assay did not reveal any modulation of
receptor activity over doses that would convey an antiparasitic effect (Fig 5A and 5E).
Third, to investigate the properties of antagonists at Sm.5HTR, we compared the action of
bromocriptine (a known ‘irreversible antagonist’ of Hs.5HTR7 [26]) with the competitive
antagonist cyproheptadine. While both antagonists acutely inhibited Sm.5HTR function (Fig
6A), inhibition evoked by bromocriptine persisted after antagonist wash-out while
forskolin (20μM) evoked changes in luminescence relative to control samples (DMSO, open circles). (E) Heat map of all test compounds
screened against S.mansoni Sm.5HTR (left) and human Hs.5HT7 (middle). Each colored box represents the fold change in luminescence in
response to an individual test compound (253 in total) keyed by the pseudocolor scale. Compounds showing activity against endogenous
receptors in cells transfected with the 22F biosensor alone (21 compounds total) were masked (black). Right, Venn diagram summarizing
selectivity of antagonist ‘hits’ against either Sm.5HTR, Hs.5HT7R, or both 5-HT receptors. In total, 23 ligands were classified as potential ‘hits’
at Sm.5HTR and 31 ligands as ‘hits’ at Hs.5HTR7, with 7 in common.
doi:10.1371/journal.ppat.1005651.g003
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Fig 4. Profiling ligand selectivity for schistosome and human 5HT7 receptors. (A) Dose response relationships for
compound antagonism of 5-HT evoked cAMP generation at human Hs.5HT7R (green) or parasite Sm.5HTR (blue) GPCRs.
Illustrative data from compounds showing preferential selectivity toward Sm.5HTR (top) or Hs.5HT7R (bottom), or compounds
with no selectivity (middle). Data represent mean±s.d, n = 3. (B) Schematic representation of ratio of IC50s for ‘hits’ profiled
against both Sm.5HTR and Hs.5HT7R expressing HEK293 cells. Compounds exhibiting poor blockade of either GPCR (*)
SchistosomeGPCR Ligand Discovery
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cyproheptadine inhibition was fully reversed by 1 hour after ligand removal (Fig 6B). Expand-
ing this assay to other ligands revealed long-lasting inhibition with several ligands previously
established as pseudo-irreversible antagonists at Hs.5HT7R (methiothepin, bromocriptine,
lisuride, risperidone and metergoline) but not with the competitive blockers clozapine and
cyproheptadine (Fig 6C and 6D). The most potent ligands were bromocriptine, methiothepin
and lisuride (Fig 6E). Therefore, although ligand specificities of these GPCRs are divergent, a
unique aspect of receptor phenomenology is conserved between the human and parasite
receptor.
Finally, we profiled compounds structurally related to those compounds prioritized from
the library screen in terms of parasite selectivity. As two of these top hits were dimethoxyiso-
quinoline derivatives (rotundine, alfuzosin) we focused on agents containing this moiety. Slight
modifications of rotundine structure were sufficient to alter the GPCR inhibition profile (Fig F
in S1 Text), as reflected by comparison of berberine/palmatine (decreased potency and selectiv-
ity for Sm.5HTR) and tetrabenazine (selectivity for Sm.5HTR retained). Similarly, comparison
of the closely related structures tetrandrine and berbamine suggested a discriminating struc-
ture-activity profile for Sm.5HTR (Fig F in S1 Text).
Evaluation of structural data from all these assays provides insight to the structural selectiv-
ity between parasite and human receptors. Fig 7 arrays worm IC50 values versus human IC50
values, such that compounds with submicromolar IC50 values and selectivity for the parasite
Sm.5HTR receptor fall into the bottom right quadrant. As expected, given the historical bias in
ligand design for affinity toward human receptors, most compounds favor the human receptor
(falling ‘above the line’ in Fig 7). For example, most of the screened tricyclic and tetracyclic
antidepressants show higher affinity for Hs.5HT7R (12/13 compounds screened). Similarly,
ligands with phenyl-sulfonyl groups (SB 269970, SB742457) that are potent inhibitors of
Hs.5HT7R [37] (Fig 4), completely lacked activity at Sm.5HTR. In contrast, compounds exhib-
iting potency and selectivity toward the parasite receptor (bottom right quadrant) were the
ergot alkaloid bromocriptine and several dimethoxyisoquinoline compounds revealed by our
experiments (rotundine, tetrabenazine, tetrandrine).
Effects of compounds on schistosomules
Do these hits from the Sm.5HTR screen in vitro translate into effectiveness against parasites?
To assess this issue, selected compounds were screened for effects on schistosomule contractil-
ity. Schistosomules exhibit a basal level of spontaneous contractile activity (Fig 8A) which pro-
vides a simple phenotype for assaying neuromuscular activity. In this system, 5-HT is
myoexcitatory: exogenous addition of 5-HT causes an increase in the basal contractile rate in a
dose-dependent manner (Fig 8B). Subsequent addition of the four compounds validated above
as potent blockers of Sm.5HTR (rotundine, tetrabenazine, tetrandrine, bromocriptine) were
examined. Three of these compounds–rotundine, tetrandrine and bromocriptine–all potently
inhibited 5-HT evoked contractions (IC501μM). Tetrabenazine was however less efficacious
in vivo, effecting only a ~50% inhibition of 5-HT evoked contractility at the highest dose
(100 μM). Therefore three of the four compounds prioritized by the Sm.5HTR screening data
conferred an inhibitory action against schistosomules.
The action of Sm.5HTR ligands were then examined against adult schistosome worms in
vitro. Isolated worms exhibited basal mobility, and application of 5-HT significantly increased
the movement of unpaired male and female worms (Fig 9A). Basal movement and the
precluded calculation of IC50 values, so a minimal ratio estimate is provided. Solid circles represent compounds for which data
is shown in ‘A’.
doi:10.1371/journal.ppat.1005651.g004
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Fig 5. Effects of ergot alkaloids on Sm.5HTR. (A) Dose response relationship for various bioaminergic ligands
reveals ergotamine and dihydroergotamine act as partial agonists at Sm.5HTR. (B-D) Bromocriptine (B),
SchistosomeGPCR Ligand Discovery
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magnitude of the 5-HT evoked stimulation differed between males and females (Fig 9A). These
effects was quantified by performing dose-response relationships (Fig 9B). Sex differences in
the magnitude of 5-HT evoked cAMP generation [38], Sm.5HTR transcript and Sm.5HTR pro-
tein expression have previously been reported [20,39]. The action of rotundine, tetrandrine
and bromocriptine were then assessed against basal (Fig 9C) and 5-HT stimulated wormmove-
ment (Fig 9D). Addition of bromocriptine and rotundine markedly inhibited worm move-
ments at rest whereas tetrandrine enhanced movements of isolated female worms (Fig 9C).
Bromocriptine and rotundine also inhibited the 5-HT evoked increases in worm movement,
and again tetrandrine lacked an inhibitory effect (Fig 9D). From these experiments, we con-
clude bromocriptine and rotundine also act as effective paralytics of adult schistosome worms.
Finally, we were interested in examining the kinetics of inhibition caused by bromocriptine
and rotundine to probe whether the protracted inhibition of Sm.5HTR observed in vitro (Fig
6) was manifest in vivo. To do these experiments, worms were exposed to bromocriptine or
rotundine, and then challenged with 5-HT at various points after drug removal. As expected
both drugs inhibited basal worm movement, and blunted 5-HT evoked stimulation (Fig 10).
The time course of reversal of these effects was then examined. For male worms, which were
effectively paralyzed by both drugs (Fig 9C), the paralytic effects of rotundine were reversed
within 3hrs of drug exposure (Fig 10A). However worms exposed to bromocriptine remained
impaired for considerably longer, with recovery of movement being only demonstrable 24hrs
after bromocriptine removal (Fig 10A). A similar timecourse of recovery from bromocriptine
exposure was also resolved for female worms (Fig 10B). These data suggest that bromocriptine
exposure evokes a protracted paralysis of adult schistosomes.
Discussion
In this study we executed a proof of principle pilot screen to evidence the feasibility of pharma-
cological profiling a flatworm GPCR in HTS format. The assay system employed relied on an
genetically encoded luminescent biosensor [23]. This is an appealing approach as this strategy
is non-destructive and affords the ability to continually monitor the kinetics of cAMP genera-
tion from a single sample. Further by directly reporting cAMP levels, rather than transcrip-
tional outcomes (e.g. cAMP reporter genes), this approach also reveals proximal receptor
activity in real time to help discern how specific compounds are modulating GPCR activity.
Acceptable Z’ scores were reliably obtained in 384 well format (Fig A in S1 Text), and we note
the sensitivity of this approach has permitted responses from endogenous GPCRs to be
resolved even in ultra-high throughput screening formats (3456-well plates). Obviously, this
particular biosensor is suited only for Gs and Gi-coupled GPCRs, but the optimization of other
biosensors—for example, genetically-encoded Ca2+ indicators [40], or reporters that are ago-
nist independent [41]—should aid HTS profiling of other flatworm GPCRs coupling to differ-
ent second messenger cascades.
Differences between human and schistosome 5-HT7 receptors
The importance of unbiased profiling of flatworm GPCR targets is underscored by visualiza-
tion of the entire dataset (Fig 3E) that underscores a divergence in ligand specificities between
the schistosome 5-HT receptor (Sm.5HTR) and the closest human homolog (Hs.5HT7R, ~30%
amino acid identity). This divergence in ligand specificity evidences concerns over use of
metergoline (C) and LSD (D) act as competitive antagonists of Sm.5HTR. (E) PZQ lacks antagonist activity at
Sm.5HTR. (F) Structure-activity-relationship for various ergoline ligands at the Sm.5HTR. Data in parentheses
represent pEC50 ± S.E.M or pKB ± S.E.M.
doi:10.1371/journal.ppat.1005651.g005
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Fig 6. Long lasting inhibition of Sm.5HT7R evoked by a subset of ligands. Sm.5HTR displays an inactivating antagonist property reported for
human 5HT7R. (A) Both the ‘inactivating antagonist’ bromocriptine (10μM, blue) and the competitive antagonist cyproheptadine (10μM, grey)
acutely inhibit the effect of 5-HT (10μM) at Sm.5HTR (5-HT alone, black). (B) Sm.5HTR remains insensitive to 5-HT following washout of
bromocriptine but not cyproheptadine. Cells were pre-incubated with antagonists as in (A) for 30 mins, followed by solution exchange, and the assay
for 5-HT responsiveness 1hr later. (C) Inhibition of 5-HT response at Sm.5HTR by both ‘inactivating antagonists’ established at Hs.5HT7R
(methiothepin, bromocriptine, lisuride, risperidone, metergoline) and competitive antagonists (clozapine, cyproheptadine). All drugs were tested at
10μM for 30mins. **, p <0.01. (D) Persistent effects of antagonists (10μM) shown in (C) after washout and subsequent assay for 5-HT response (1hr
later). **, p <0.01, *, p <0.05. (E) Titration of these ‘inactivating antagonists’ revealed the dose-response relationship for Sm.5HTR inhibition after
washout. Colors correspond to drug identity in C&D. Data represent mean±s.e.m., n = 3 (C-E).
doi:10.1371/journal.ppat.1005651.g006
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established mammalian ligands to infer flatworm physiological mechanisms as many chemical
probes used to study human 5HT7 receptors have modest effects on Sm.5HTR at similar con-
centrations. Examples include the sulfonyl derivatives SB269970, SB742457 and amisulpiride
(Fig 4). The fact that 5-HT receptors in different organisms have evolved divergent characteris-
tics profiles is of course unsurprising: the adult schistosome lives within the human host circu-
latory system, a 5-HT rich environment, where it continuously ingests and cycles 5-HT replete
cells. The characteristics of the ligand binding site of Sm.5HTR may therefore necessitate
Fig 7. Structure activity relationships for various drug classes against Hs.5HT7R and Sm.5HTR.
Comparison of IC50s for compounds inhibiting cAMP generation via Hs.5HT7R (abscissa) or Sm.5HTR
(ordinate). Compounds with no preferential selectivity for either receptor, showing similar IC50s, would cluster
along the solid line. Hits in the lower right quadrant (red square) show sub-μM potency at Sm.5HTR but
supra-μM potency at Hs.5HT7R. Four compounds meet this criterion (bromocriptine = ‘39’, rotundine = ‘37’,
tetrandrine = ‘31’ and tetrabenazine = ‘32’). Compound classes are indicated as follows: ergot alkaloids
(green), isoquinolines (blue), tricyclic and tetracyclic antidepressants (magenta), sulfonyl compounds
(orange), miscellaneous structures (open). Individual compounds are: 1, SB269970; 2, amisulpride; 3,
SB742457; 4, olanzapine; 5, mianserin; 6, quetiapine; 7, clozapine; 8, cyproheptadine; 9, ketotifen; 10,
loratadine; 11, maprotiline; 12, clomipramine; 13, desloratadine; 14, rupatadine; 15, vortioxetine; 16,
amitriptyline; 17, risperidone; 18, domperidone; 19, chlorprothixene; 20, clemastine; 21, aripiprazole; 22,
ketanserin; 23, ifenprodil; 24, tripelennamine; 25, fluoxetine; 26, atomoxetine; 27, orphenadrine; 28, lisuride;
29, benztropine; 30, cyclizine; 31, tetrandrine; 32, tetrabenazine; 33, berberine; 34, 6, 7-diethoxy-1, 2, 3,
4-tetrahydroisoquinoline; 35, corynoline; 36, alfuzosin; 37, rotundine; 38, fanchinoline; 39, bromocriptine; 40,
metergoline; 41, LY215840; 42, nicergoline; 43, mesulergine; 44, dihydroergocristine.
doi:10.1371/journal.ppat.1005651.g007
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Fig 8. Small molecule inhibitors of Sm.5HTR antagonize 5-HT stimulation of schistosomule contractility. Effects of selected ligands
on schistosomules. (A) 5-HT stimulates basal contractility in S.mansoni schistosomules resolved through measurements of body length
over time (1 minute recording duration). A contractile cycle is defined when a deviation of20% of the average body length (dashed lines)
occurs. (B) Dose-response curve for 5-HT stimulation of contractility. (C) Schistosomule movement was quantified for basal mobility (i, no
5-HT addition; white bars), after addition of 5-HT ((ii, 10μM 5-HT; grey bars), and subsequent exposure to Sm.5HTR inhibitors in the
presence of 5-HT (iii, indicated doses; black bars). Representative body length traces over one minute for individual schistosomules are
shown for indicated conditions (right). Bar graphs represent mean±s.e.m. of independent samples, n = 3. Drugs assayed represent ligands
identified as Sm.5HTR antagonists in the GPCR screen (rotundine), and follow up testing of methoxyisoquinoline compounds (tetrandrine,
tetrabenazine) and the ergot alkaloid bromocriptine.
doi:10.1371/journal.ppat.1005651.g008
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adaptations to this niche. While this pharmacological divergence may limit repurposing efforts
for existing serotonergic ligands that have been optimized toward human usage, it is neverthe-
less encouraging for de novo ligand discovery if pharmacological differences between flatworm
and human receptors can be exploited to selectivity target parasite biology.
In this regard, our data identified several ligands were identified with a preference for
Sm.5HTR over Hs.5HT7R, and reciprocally several ligand classes were deprioritized owing to
an observed preferential selectivity for the human receptor (‘above the line’ in Fig 7B). These
latter groupings included the sulfonyl derivatives discussed above, as well as tricyclic and tetra-
cyclic antidepressants which have previously been shown to cause schistosomule hyperactivity
[42], likely through inhibition of monoamine transporters [43]. Although features of these
drugs that convey potency in schistosomules have been identified [42], these features do not
necessarily convey selectivity (over Hs.5HT7R, or human 5-HT transporters). A similar case
could be made for many ergot alkaloids, with the noted exception of bromocriptine, which was
the only ergot screened to date exhibiting higher selectivity (~10-fold) for the parasitic 5-HT
receptor (Fig 7). We had previously shown bromocriptine to displace 3H-dopamine in planar-
ian binding assays [14], but clearly bromocriptine also possess potent anti-serotonergic
Fig 9. Sm.5HTR inhibitors antagonize basal and 5-HT stimulatedmovement in adult schistosomes. (A) Movement of adult
male (top) and female (bottom) schistosomes under basal conditions (no 5-HT) and in the presence of 5-HT (100μM, arrow). Traces
represent one minute of recorded movement for each condition. Scale, 1cm. (B) Dose response curves showing movement of male
(solid circles) and female (open circles) schistosomes exposed to increasing concentrations of 5-HT. (C) Left, effect of bromocriptine
(10μM) on the basal movement of adult male and female schistosomes. Representative traces showing the movement of worms in
the absence of drug (black) and the presence of bromocriptine (red). Right, quantification of basal movement for male (solid bars) and
female (open bars) worms exposed to the indicated compounds. (D) Left, effect of bromocriptine (10μM) on 5-HT (100μM) stimulated
movement of adult schistosomes. Representative movement of worms exposed to 5-HT alone (black) or bromocriptine and 5-HT
(red). Right, quantification of 5-HT stimulated movement for male (solid bars) and female (open bars) worms exposed to the indicated
compounds. n3 independent experiments. * p < 0.05, ** p < 0.01.
doi:10.1371/journal.ppat.1005651.g009
Fig 10. Long lasting inhibition of schistosomemovement caused by bromocriptine. Time course of schistosome recovery from exposure to
Sm.5HTR antagonists (black = DMSO control, blue = rotundine, red = bromocriptine). Mobility of worms was recorded following exposure to
antagonist (10μM, ‘drug’, 2 hour exposure) and addition of 5-HT (100μM, ‘drug + 5-HT’). Media was then exchanged, and recordings were
subsequently made on the same worms stimulated with 5-HT (100μM) at the indicated timepoints (3, 6, 24hrs after drug washout). Data for males
(A) and females (B) is presented normalized to basal movement of control (dmso) worms in the absence of 5-HT.
doi:10.1371/journal.ppat.1005651.g010
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properties in flatworms consistent with the polypharmacology of ergot alkaloids. The antago-
nist effect of LSD against Sm.5HTR (Fig 5B) was also unexpected, given LSD action as a seroto-
nergic agonist in mammals. Further attention is needed to identify features of the ergoline
scaffold that convey preferential modulation of parasitic 5-HTRs, given the ~100-fold range in
IC50s observed (Fig 7).
In contrast to the observed human bias of many ligands, several compounds with preferen-
tial selectivity toward Sm.5HTR were resolved (Figs 4B and 6B). First, several modulators of
biogenic amine transport, represented by compounds such as atomoxetine and fluoxetine. Flu-
oxetine is a serotonin reuptake inhibitor while atomexetine, a non-halogenated derivative of
fluoxetine, is employed as a norepinephrine transporter inhibitor. Compounds of this class are
known to block 5-HT GPCRs [44]. Second, and perhaps most striking, were ligands containing
dimethoxyisoquinoline moieties (blue, Fig 7), several of which exhibited clear bias toward
Sm.5HTR. These included two compounds with prior precedent as bioaminergic blockers—
alfuzosin, a mammalian adrenergic (μ1) blocker, and rotundine which inhibits dopamine and
serotonin binding at D1, D2 and 5-HT1A GPCRs [45]. Rotundine potently inhibited Sm.5HTR
(IC50 ~700nM) while lacking any effect on Hs.5HT7 at concentrations up to 50μM. Chemical
exploration of this scaffold is therefore further warranted, especially in light of the small num-
ber of compounds screened in this study. We also note that the stalwart anthelmintic PZQ is
also a isoquinoline derivative, although direct interrogation of PZQ against Sm.5HTR did not
yield any effect (Fig 5A and 5E). This does not preclude the possibility that PZQ acts as a ligand
at another flatworm bioaminergic GPCR [13], one explanation for the functional antagonism
observed between PZQ and 5-HT in planarians [13], schistosomules [13] and adult schisto-
somes [28,46].
Subsequent screening of bromocriptine (the most parasite selective ergot alkaloid, Fig 7),
and the three promising isoquinoline ‘hits’ against both schistosomules and adult worms (Figs
8 and 9) revealed a clear inhibition of 5-HT evoked hypermotility from two of the four com-
pounds (bromocriptine, rotundine) prioritized from the screen of heterologously expressed
Sm.5HTR. The two other Sm.5HTR ligands (tetrabenazine, tetrandrine) were poorly effective.
Such attrition of leads is expected when advancing candidates identified in vitro. For example,
the stimulatory action of tetrandrine against adult worms (Fig 9), not observed in the schistoso-
mule dataset (Fig 8), may reflect a counteracting stimulatory action at other schistosome
GPCRs upregulated at the adult stage. Differences in GPCR expression [39] may also contrib-
ute to the observed differences in drug and 5-HT action between male and female worms (Fig
9). Overall, this was an encouraging translation from in vitro data to activity against different
parasite life cycle stages, supporting the rational design and development of antiparasitic drugs
aimed at schistosomal GPCRs.
Similarities between human and schistosome 5-HT7 receptors
Despite the divergence in pharmacological selectivity between the human and schistosome
5-HT GPCRs, it is worthwhile highlighting an important similarity between these receptors
which may prove a boon for anthelmintic development. The human Hs.5HT7R is induced into
a prolonged inactivated state by exposure to a subset of ligands, termed ‘inactivating antago-
nists’ [25,26]. These inactivating antagonists are structurally diverse and include the ergot alka-
loid bromocriptine, risperidone, methiothepin, lisuride and metergoline [26]. Application of
these ligands caused a prolonged inactivation of Hs.5HT7R activity in heterologous expression
systems or in assays on endogenous receptors [25,26,47]. Data suggests this aspect of receptor
phenomenology may be conserved with Sm.5HTR, the most abundant deorphanized GPCR in
adult schistosome worms, when evaluated in receptor level (Fig 6) and whole organism assays
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(Fig 10). The predominant expression of this specific GPCR in this organism, together with
conservation of this receptor property, provides a clearly targetable weakness for anthelmintic
development. If transient exposure to an inactivating antagonist inhibits parasite mobility well
beyond the pharmacokinetic persistence of the drug within an infected individual, this would
be clearly be effective for antiparasitic action and serve to minimize dosing requirements in
challenging healthcare environments. Sm.5HTR is also expressed at multiple life cycle stages,
and is conserved in other PZQ-sensitive parasites. Further exploration of this property and
identification of parasitic-selective ligands that convey this effect are warranted, and such activ-
ities will be facilitated by the approaches optimized in this study.
In conclusion, these data demonstrate the optimization and application of a real-time bio-
sensor assay for interrogating flatworm GPCRs in vitro, which is capable of scaling to HTS.
Application of this approach to profile Sm.5HTR revealed parasitic-selective ligands and ligand
series, as well as conservation of a ligand-evoked inactivation mechanism at the most predomi-
nantly expressed S.mansoni 5HTR.
Materials and Methods
Compounds & reagents
Serotonin (5-HT), 3-Isobutyl-1-methylxanthine (IBMX) and DMSO were purchased from
Sigma Aldrich. The GPCR Compound Library was purchased from Selleck Chemicals (Catalog
No. L2200) pre-dissolved in DMSO (10mM). 5HT7 ligands DR4485, LY215840, metergoline
and 5-Carboxamidotryptamine (5-CT) were purchased from Tocris Bioscience. Methoxy-iso-
quninoline alkaloids (rotundine, tetrabenazine, berbine, palmatine, tetrandrine and berba-
mine) were purchased from Sigma Aldrich, while fangchinoline was purchased from AK
Scientific.
Cell culture and 5-HT receptor expression
HEK293 cells (ATCC CRL-1573.3) were cultured in DMEM supplemented with 10% fetal
bovine serum (FBS), penicillin (100 units/ml), streptomycin (100 μg/ml), and L-glutamine
(290 μg/ml). Cells were transiently transfected (ViaFect, Promega) as per the manufacturer’s
protocol at a density of 2x106 cells per T-25 cell-culture flask. Cells were transfected with plas-
mids encoding GloSensor (Promega) and either Sm.5HTR (Smp_126730, GenBank accession
number KF444051.1) or Sm.5HTRL (KX150867), bothGPCRs being codon optimized for
mammalian expression, or Hs.5HT7a (GenBank accession number NM_000872.4, R&D Sys-
tems) subcloned into pCS2(-). Cell culture reagents were from Invitrogen. Epitope tagged con-
structs were used to verify expression, and untagged constructs used for all luminescence
assays.
Western blotting
HEK293 cells were transfected with Sm.5HTR subcloned into a pCS2(-) mammalian expres-
sion vector possessing an NH2-terminal 6xmyc tag and harvested 24 hours post-transfection.
Cell pellets were solubilized in 1% NP-40, protein was quantified using Bradford reagent
(Pierce). Denatured sample (10 μg) was run on a Mini-PROTEAN TGX Precast Gel (BioRad)
at 150V. Semi-dry transfer to PVDF membrane was performed using a Trans-Blot Turbo
Mini-PVDF Transfer pack (Bio Rad) at 25V for 30 minutes. The membrane was blocked with
5% nonfat milk in TBST (Tris-buffered saline, 0.1% Tween 20) for 1hr at room temperature,
incubated with anti-myc antibody overnight at 4°C (Santa Cruz, 1:500 dilution in 5% milk
-TBST) prior to washing in TBST (3x10 minutes) and incubation with secondary antibody
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(LiCor Goat anti-mouse IRDye 800, 1:5000 dilution in 5% milk -TBST) for 1hr at room tem-
perature. After washing (3x10 minutes in TBST), membranes were visualized on a LiCor Odys-
sey imaging system.
Molecular cloning
Sequence for Sm.5HTRL was determined by cloning from an Schistosoma mansoni cDNA
library (adult male and female NMRI strain, BEI cat #NR-36056) using high fidelity Advantage
HD DNA polymerase (Clontech) and primers described in [20]. PCR products were ligated
into the pGEM-T Easy vector system (Promega) prior to DNA sequencing. Additional
sequence contained in the Sm.5HTRL isoform was verified by 5’/3’ RACE (SMARTer RACE
Kit, Clontech) using total RNA extracted from S.mansoni (Trizol reagent, Ambion). Products
were cloned into the pRACE vector (In-Fusion HD Cloning Kit, Clontech) prior to DNA
sequencing.
GloSensor cAMP assays
For assays performed on adherent cells, HEK-293 cells were transferred one day post transfec-
tion to 96 well, solid white plates (Corning, cat # 3917) coated with 0.01% poly-L-lysine (Sigma
Aldrich) at a density of 5 x 104 cells / well in DMEM supplemented with 1% dialyzed FBS
(Gibco). After overnight culture (37°C/5% CO2), media was decanted and replaced with 100μL
/ well HBSS supplemented with 0.1% BSA, 20mMHEPES (pH 7.4) and GloSensor reagent.
Plates were allowed to equilibrate at room temperature for two hours prior to performing lumi-
nescence assays (GloMax-Multi Detection System plate reader, Promega). Conditions for indi-
vidual assays were described as per figure legends. The standard assay to detect changes in
cAMP utilized the F22 sensor in media supplemented with IBMX (200μM). Ligands were
added at a concentration of 20x per well for experiments (i.e. 5μl of drug solution added to
100μl of cells). A dose of 5-HT corresponding to the [EC80] for the relevant receptor used for
all antagonist screens. The average standard deviation of the 5-HT Emax in internal, vehicle
treated control wells (at least 8 per plate) was 13% for Sm.5HTR and 8% for Hs5HT7R. For the
resazurin reduction assay for cellular viability, cells were incubated with resazurin (final con-
centration, 10μM) and tested ligands with fluorescence measurements (560 nm excitation/590
nm emission) made at 1.5hr intervals.
To test putative irreversible antagonists, assays on suspension cells were performed one day
post transfection. Cells in a T-75 flask were trypsinized (0.25% w/v) and transferred to a 14mL
tube, centrifuged at 300 RCF, and resuspended in HBSS supplemented with 0.1% BSA, 20mM
HEPES. Compounds were added at 10 μM, and after 30 minute incubation at room tempera-
ture cells were centrifuged (300 RCF, 5 minutes) and resuspended in fresh media. This wash
step was repeated, and cells were resuspended in HBSS supplemented with 0.1% BSA, 20mM
HEPES and GloSensor reagent. Cells were gently rotated to prevent aggregation and settling
over the course of the two hour equilibration period, after which time they were transferred to
96 well plates at a density of 8 x 104 cells / 100μL per well and assays described for adherent
cells.
Schistosomule assays
Biomphalaria glabrata (M-line) snails exposed to Schistosoma mansonimiracidia (Strain PR-1)
were obtained from BEI Resources (Cat. number NR-21961) and cercaria were shed following
exposure to light (1.5 hours). Cercaria were manually transformed into schistosomula by vor-
texing (3 x 45 seconds, each separated by 3 minutes on ice) and tails were removed by gradient
centrifugation (24ml Percoll, 4ml 10X EMEM, 1.5ml penicillin-streptomycin, 1ml of 1M
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HEPES in 0.85% NaCl, 9.5ml distilled water) at 500g/15min at 4°C. Supernatant containing
tails was discarded, and schistosomules were resuspended in Basch media and incubated
(37°C, 5% CO2) overnight before conducting mobility assays. For contractility experiments,
somules were incubated in 5-HT free Basch media to resolve a basal contractility rate. To estab-
lish a dose response curve for 5-HT, serial dilutions of 5-HT were added to Basch media and
somule contractile frequency recorded. In order to assess the effects of antagonists on somule
movement, recordings were made of cohorts in 5-HT free Basch media, media supplemented
with 5-HT (10μM), and media supplemented with both 5-HT (10μM) and the drugs indicated
in Fig 8. Schistosomules were incubated in 24 well plates (~200 schistosomules / 0.5mL media
per well) for 30 minutes (37°C/5% CO2) prior to acquiring videos of schistosome movement (1
minute recordings / well) using a Nikon Coolpix 5700 camera affixed to a Nikon Eclipse TS100
microscope (10x objective). The WrmTrck plugin for ImageJ was used to quantify worm
mobility [21]. Briefly, the major axis of each schistosomule body length was extracted from the
raw output of WrmTrck and an average length was determined for the duration of the record-
ing. Contractions were quantified by determining the number of episodes during which the
worm body length deviated from the average by over 20%. S.mansoni protocols were approved
by the Iowa State University Institutional Biosafety Committee.
Adult schistosome mobility assays
Female Swiss Webster mice exposed to Schistosoma mansoni cerceria (Strain PR-1) at 5–7
weeks old were obtained from BEI Resources (Cat. number NR-34792) and sacrificed 6–8
weeks post-infection. Mature S.mansoni were harvested from the mesenteric vasculature by
portal perfusion [48]. Briefly, mice were anesthetized in a CO2 chamber and sacrificed by cervi-
cal dislocation. Mice were perfused with sodium citrate (25mM) and adult schistosomes were
harvested from the mesenteric veins. Schistosomes were washed in RPMI media containing
penicillin (1000 units/mL), streptomycin (1000 μg/mL) and 25mMHEPES, then transferred to
RPMI media supplemented with 2mM glutamine and 5% heat inactivated FBS. Worms were
incubated overnight at 37°C, 5% CO2 before conducting assays. Recordings of adult schisto-
some movement were captured using a Zeiss Discovery v20 stereomicroscope and a QiCAM
12-bit cooled color CCD camera. Videos were acquired at a rate of four frames per second for
one minute. Recordings of female worms were acquired at 7.6x magnification, 30 mm field of
view and recordings of male worms were acquired at a 5.1x magnification, 45 mm field of view.
Analysis was performed in ImageJ as described previously [20]. Briefly, image (.tiff) stacks of
each recording were imported and processed by converting to binary format so that pixel mea-
surements represent area of the worms’ bodies. Mobility was quantified by measuring the dif-
ference in pixels resulting from subtracting the value of one frame (n) from those of the next
frame in the sequence (n+1). This difference was expressed as a percentage of the pixels in the
initial frame (n), providing a measurement of the worms’movement over a period of 0.25 sec-
onds. This calculation was performed for each frame in the video, and the results were averaged
over the length of the recording. Values reported represent the mean (±) standard error of at
least three independent experiments. Animal work was carried out with the oversight and
approval of the Laboratory Animal Resources facility at the Iowa State University College of
Veterinary Medicine.
Supporting Information
S1 Text. Figure A. Sm.5HTR GloSensor luciferase assay in 384 well plate format. (A) HEK293
cells transiently transfected with Sm.5HTR and the F22 cAMP biosensor were assayed for
changes in luminescence in response to addition of 5-HT (10μM, arrow). (B) Dose response
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curve depicting luminescence values assayed 60 mins following 5-HT addition. (C) Z’-scores
over time illustrated for the representative experiment shown in (A). All experiments shown
performed in the presence of IBMX (200μM). Figure B. Sm.5HTR response to bioaminergic
ligands. (A) Response of HEK293 cells transfected with the F22 GloSensor to various Class A
GPCR ligands (10μM), revealing a lack of responsiveness to serotonergic ligands but robust
cAMP generation in response to catecholamines acting on endogenous HEK293 cell GPCRs.
(B) Response of HEK293 cells co-expressing Sm.5HTR and the F22 biosensor to various sero-
tonergic and monoaminergic ligands previously identified to lack activity on endogenous Gs
coupled GPCRs. Figure C. Comparison of ligand class specificities against Sm.5HTR and
Hs.5HT7R. Categorized ligand specificities of individual compounds that block Sm.5HTR and
Hs.5HTR7 from classification index of the screened library. While Sm.5HTR and Hs.5HTR7
show distinct selectivity profiles to the 23 and 31 ligands identified as ‘hits’, the broader classifi-
cation of these ligands is similar. Figure D. Effect of Sm.5HTR antagonists on Sm.5HTRL.
Luminescence response from Sm.5HTRL expressing HEK293 cells to 5-HT (EC80
dose = 0.8μM) in the presence of indicated antagonists (10μM). Data are shown relative to con-
trol samples unexposed to antagonist (black). Antagonist compounds screen encompass com-
pounds from the GPCR library screen (grey), methoxy-isoquinolines (open), and ergot
alkaloids (striped).Figure E. Toxicity test for screened compounds. (A) HEK293 cells tran-
siently transfected with the F22 cAMP biosensor were incubated with test compounds (10μM,
30 mins) and then assayed for forskolin (20μM, 30 mins) evoked cAMP generation. Tested
ligands showed no effects on luminescence signal values. The mitochondrial complex I inhibi-
tor rotenone served as a positive control. (B) Resazurin reduction assay for cell viability of
HEK293 cells exposed to test compounds (10μM) and resazurin (10μM) for 3 hours at 37°C.
Fluorescence was measured using a 560nm excitation/590nm emission filter set. Sodium azide
was used as a positive control. Figure F. Effects of selected compounds on Sm.5HTR and
Hs.5HT7R evoked cAMP generation. (A) Inhibition curves shown for the following methoxy-
isoquinoline related compounds against Sm.5HTR (blue) and Hs.5HT7R (green): (i) rotundine
(data reproduced from Fig 4A), (ii) palmatine, (iii) berberine and (iv) tetrebenazine. (B) Com-
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